After achieving a landmark settlement, in which the negligent defendants have agreed to fund immunotherapy for a claimant who has developed cancer, Michael Rawlinson QC examines the dilemma of the prospect and effect of immunotherapy in a recent blog post.

The full blog post can be found here.